Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.64 |
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | TP53 | P04637 | 6/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.64 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.64 |
| ▸ | POLH | Q9Y253 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | HPGD | P15428 | 5/20 | 0.64 |
| ▸ | XDH | P47989 | 5/20 | 0.64 |
| ▸ | DAPK1 | P53355 | 5/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22142507 | 0.85 | MEN1 (0.61) | MEN1KMT2ACYP3A4KDM4EMAPT | |
| SCHEMBL5040391 | 0.85 | MEN1 (0.70) | MEN1KMT2ACYP3A4KDM4EMAPT | |
| SCHEMBL14685804 | 0.84 | GAA (0.66) | MEN1KMT2ACYP3A4KDM4EMAPT | |
| SCHEMBL30684642 | 0.84 | CYP3A4 (0.78) | MEN1KMT2ACYP3A4KDM4EMAPT | |
| SCHEMBL2565483 | 0.84 | CYP3A4 (0.78) | MEN1KMT2ACYP3A4KDM4EMAPT | |
| SCHEMBL12470191 | 0.84 | KDM4E (0.47) | MEN1KMT2ACYP3A4KDM4EMAPT | |
| SCHEMBL15955977 | 0.83 | AR (0.55) | MEN1KMT2ACYP3A4KDM4EMAPT | |
| SCHEMBL7087127 | 0.82 | MEN1 (0.62) | MEN1KMT2ACYP3A4KDM4EMAPT | |
| SCHEMBL3358058 | 0.81 | CYP3A4 (0.64) | MEN1KMT2ACYP3A4KDM4EMAPT | |
| SCHEMBL3051862 | 0.81 | GLO1 (0.58) | MEN1KMT2ACYP3A4KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112107530-B | Anti-aging composition | 佐登妮丝（广州）美容化妆品有限公司 | 2021-12-21 | — | — | CN | claimed |
| CN-112107530-A | Anti-aging composition | 佐登妮丝（广州）美容化妆品有限公司 | 2020-12-22 | — | — | CN | claimed |
| CN-114836489-B | Preparation method of 3' -hydroxy genistein | 佐登妮丝国际股份有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-114836489-B | Preparation method of 3' -hydroxy genistein | 佐登妮丝国际股份有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-117837498-A | Method for improving and regulating synthesis of flavonoids in saussurea involucrata leaves | 石河子大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-116509839-A | Application of 6-hydroxy genistein in preparing anti-altitude anoxia medicine | 西安交通大学医学院第一附属医院 | 2023-08-01 | — | — | CN | disclosed |
| CN-116407532-A | Application of 8-hydroxy genistein in preparing medicine for resisting altitude anoxia | 马慧萍 | 2023-07-11 | — | — | CN | disclosed |
| US-20230190702-A1 | A COMPOSITION FOR IMPROVING QOL OF A 40-YEAR-OLD OR OLDER POSTMENOPAUSAL WOMAN WITHOUT MENOPAUSAL DISORDER | DAICEL CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| CN-115697086-A | Composition for improving QOL of women over 40 years old without climacteric disturbance after amenorrhea | 株式会社大赛璐 | 2023-02-03 | — | — | CN | disclosed |
| CN-114836489-A | Preparation method of 3' -hydroxy genistein | 佐登妮丝国际股份有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114836489-A | Preparation method of 3' -hydroxy genistein | 佐登妮丝国际股份有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-107441079-B | Medicine for treating cardiovascular and cerebrovascular diseases and preparation method and application thereof | 四川省中医药科学院 | 2021-03-26 | — | — | CN | disclosed |
| WO-2017065515-A1 | COMPOSITION FOR PREVENTING OR TREATING GYNECOLOGICAL CANCERS AND MENOPAUSAL SYMPTOMS CONTAINING FLEMINGIA STROBILIFERA EXTRACT OR COMPOUND ISOLATED THEREFROM AS ACTIVE INGREDIENT | 숙명여자대학교 산학협력단 | 2017-04-20 | — | — | WO | disclosed |
| EP-2672964-B1 | COMPOSITION FOR USE IN THE TREATMENT OF MENOPAUSE PROBLEMS/DISORDERS | PALADIN PHARMA S P A (IT) | 2016-06-01 | — | — | EP | disclosed |
| EP-2672964-A1 | COMPOSITION FOR USE IN THE TREATMENT OF MENOPAUSE PROBLEMS/DISORDERS AND IN THE TREATMENT OF GENERAL AGING OF THE ORGANISM | Paladin Pharma S.p.A. (IT) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012107905-A1 | COMPOSITION FOR USE IN THE TREATMENT OF MENOPAUSE PROBLEMS/DISORDERS AND IN THE TREATMENT OF GENERAL AGING OF THE ORGANISM. | PALADIN PHARMA S.P.A. (IT) | 2012-08-16 | — | — | WO | disclosed |
| US-20090221690-A1 | Pharmaceutical Composition for the Prevention/Treatment of Bone Disorders and a Process for the Preparation Thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (US) | 2009-09-03 | — | — | US | disclosed |
| US-7084265-B1 | Polynucleotide encoding 2-hydroxyisoflavanone synthase | NIHON UNIVERSITY (JP) | 2006-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221690-A1 | Pharmaceutical Composition for the Prevention/Treatment of Bone Disorders and a Process for the Preparation Thereof | SOST, BPGM, PTMS | MEN1 197/4885KMT2A 4140/4885CYP3A4 702/4885 |
| US-20230190702-A1 | A COMPOSITION FOR IMPROVING QOL OF A 40-YEAR-OLD OR OLDER POSTMENOPAUSAL WOMAN WITHOUT MENOPAUSAL DISORDER | SHBG, UBQLN2, ELOVL5 | MEN1 3066/4885KMT2A 3713/4885CYP3A4 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.